Taurine Restoration

Taurine is one of the most abundant amino acids in the human body, and in 2023 it became one of the most discussed longevity molecules after a large, multi-species study reported that its decline might be a driver of aging.

The original 2023 Science paper, led by Vijay Yadav's group with senior authors including Rafael de Cabo and David Sinclair, measured blood taurine across mice, monkeys, and humans and reported that circulating taurine concentration falls with age in all three species [1]. In mice, daily oral taurine supplementation from middle age extended median lifespan by 10-12% and increased life expectancy at 28 months by roughly 18-25%. Taurine-fed mice also showed reduced DNA damage, less telomerase deficiency, better mitochondrial function, and fewer senescent cells, and in monkeys, taurine supplementation improved several health measures including bone density and immune markers, though the monkey study measured healthspan markers, not lifespan [2]. In humans, the paper reported that lower taurine levels correlated with several age-related diseases and that taurine rose after acute endurance exercise. The paper explicitly called for human clinical trials to test whether taurine deficiency drives aging in people, language that flags the human causal claim as untested, not established.

That call for caution turned out to be prescient in an unusual way: a direct correction came from inside the same research circle. In 2025, Rafael de Cabo, a co-author of the original 2023 paper now at the National Institute on Aging, led a new analysis using multiple independent metabolomics datasets spanning humans, mice, and monkeys. The result, published in Science, found that taurine does not reliably decline with age in healthy individuals; instead, there was more variability between different population groups and between individuals within those groups than there was across the lifespan of any one group [3]. De Cabo told reporters that when he first read the 2023 paper, something didn't click for him, which led him to pull metabolomics data from colleagues studying different human, mouse, and monkey populations. The 2025 analysis concludes taurine is not a useful biomarker for aging, and that supplementation efforts inspired by the earlier paper were, in de Cabo's words, likely premature [3].

This is the central story of taurine as a longevity molecule: the mouse lifespan-extension data from 2023 has not been retracted or directly contradicted, but the human biomarker claim that made taurine newsworthy, the idea that your blood taurine falls as you age and that this decline is something to correct, has been directly disputed by one of the original paper's own senior authors using broader population data. De Cabo's point is not narrowly technical; he used the episode to warn the public more generally, saying that whenever a paper on supplements and aging comes out, people rush to buy the supplement, and arguing results need to be read in context before triggering that kind of rush [3].

Bryan Johnson's Blueprint protocol includes taurine as one of dozens of daily supplement ingredients; it is one self-experiment with instrumented blood-marker tracking, not independent evidence that taurine supplementation slows human aging, and Johnson's continued use predates the 2025 correction.

The practical reader takeaway is unusually direct for this field: the mouse lifespan data for taurine is real and published, but the human rationale that made taurine a supplement-aisle staple, an age-related decline needing correction, has been walked back by the very lab network that helped establish it.

Products with this: Taurine